JP2021534115A - Ｂ細胞悪性腫瘍の処置 - Google Patents

Ｂ細胞悪性腫瘍の処置 Download PDF

Info

Publication number
JP2021534115A
JP2021534115A JP2021506716A JP2021506716A JP2021534115A JP 2021534115 A JP2021534115 A JP 2021534115A JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021534115 A JP2021534115 A JP 2021534115A
Authority
JP
Japan
Prior art keywords
alkyl
enantiomers
heterocyclyl
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506716A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020036999A5 (https=
JP2021534115A5 (https=
Inventor
ピー． ゴールド，ダニエル
Original Assignee
エムイーアイ ファーマ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムイーアイ ファーマ，インク． filed Critical エムイーアイ ファーマ，インク．
Publication of JP2021534115A publication Critical patent/JP2021534115A/ja
Publication of JPWO2020036999A5 publication Critical patent/JPWO2020036999A5/ja
Publication of JP2021534115A5 publication Critical patent/JP2021534115A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021506716A 2018-08-14 2019-08-13 Ｂ細胞悪性腫瘍の処置 Pending JP2021534115A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862718929P 2018-08-14 2018-08-14
US62/718,929 2018-08-14
US201862775797P 2018-12-05 2018-12-05
US62/775,797 2018-12-05
US201962836511P 2019-04-19 2019-04-19
US62/836,511 2019-04-19
PCT/US2019/046411 WO2020036999A1 (en) 2018-08-14 2019-08-13 Treatment of b cell malignancies

Publications (3)

Publication Number Publication Date
JP2021534115A true JP2021534115A (ja) 2021-12-09
JPWO2020036999A5 JPWO2020036999A5 (https=) 2022-08-19
JP2021534115A5 JP2021534115A5 (https=) 2022-08-19

Family

ID=69525845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506716A Pending JP2021534115A (ja) 2018-08-14 2019-08-13 Ｂ細胞悪性腫瘍の処置

Country Status (14)

Country Link
US (1) US20210299134A1 (https=)
EP (1) EP3836935A4 (https=)
JP (1) JP2021534115A (https=)
KR (1) KR20210043635A (https=)
CN (1) CN112888441A (https=)
AU (1) AU2019321432A1 (https=)
BR (1) BR112021002760A2 (https=)
CA (1) CA3109184A1 (https=)
IL (1) IL280726A (https=)
MA (1) MA53236A (https=)
MX (1) MX2021001606A (https=)
SG (1) SG11202101450VA (https=)
TW (1) TW202021591A (https=)
WO (1) WO2020036999A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509647A (ja) * 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
WO2018053437A1 (en) * 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2648676A4 (en) * 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
PT3262071T (pt) * 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2017035234A1 (en) * 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3487878A4 (en) * 2016-07-20 2020-03-25 University of Utah Research Foundation CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018082444A1 (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509647A (ja) * 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
WO2018053437A1 (en) * 2016-09-19 2018-03-22 Mei Pharma, Inc. Combination therapy

Also Published As

Publication number Publication date
CA3109184A1 (en) 2020-02-20
EP3836935A1 (en) 2021-06-23
IL280726A (en) 2021-03-25
MA53236A (fr) 2021-06-23
MX2021001606A (es) 2021-04-19
US20210299134A1 (en) 2021-09-30
EP3836935A4 (en) 2022-09-14
BR112021002760A2 (pt) 2021-05-11
SG11202101450VA (en) 2021-03-30
AU2019321432A1 (en) 2021-03-25
TW202021591A (zh) 2020-06-16
WO2020036999A1 (en) 2020-02-20
KR20210043635A (ko) 2021-04-21
CN112888441A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
US12157735B2 (en) Compounds for targeted degradation of BRD9
US12590062B2 (en) PD-1/PD-L1 inhibitors
JP6779870B2 (ja) 抗増殖性化合物及びその使用方法
CN112585136B (zh) 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
AU2021257373B2 (en) Pyridopyrimidinone derivatives and their use as Aryl hydrocarbon receptor modulators
TW201737913A (zh) Tank－結合激酶抑制劑化合物
JP2021517116A (ja) 併用療法
IL272166B (en) A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
JP2024522189A (ja) Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN112739420A (zh) 苯氧基-吡啶基-嘧啶化合物及使用方法
JP2020531414A (ja) 併用療法
JP2025538228A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
JP2024522188A (ja) Ｆｇｆｒ阻害剤としての三環式ヘテロ環
JP2021534115A (ja) Ｂ細胞悪性腫瘍の処置
JP2021534116A (ja) 再発性の濾胞性リンパ腫の処置
JP2021534114A (ja) 併用療法
CN112689528B (zh) 嘧啶基-杂芳氧基-萘基化合物和使用方法
EP4587429A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
KR20260004307A (ko) 다환성 irak 및 flt3 억제 화합물 및 이의 용도
KR20230135541A (ko) 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도
HK40051446A (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220810

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231221